Cargando…

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency

BACKGROUND: Computed tomography (CT) lung densitometry has been demonstrated to be the most sensitive and specific outcome measure for the assessment of emphysema-modifying therapy, but the optimum densitometric index has yet to be determined and targeted sampling may be more sensitive than whole lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parr, David G, Dirksen, Asger, Piitulainen, Eeva, Deng, Chunqin, Wencker, Marion, Stockley, Robert A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740846/ https://www.ncbi.nlm.nih.gov/pubmed/19678952 http://dx.doi.org/10.1186/1465-9921-10-75

Ejemplares similares

Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry
por: Stockley, Robert A, et al.
Publicado: (2010)

Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; Methodological advances
por: Parr, David G, et al.
Publicado: (2008)

Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency
por: Mostafavi, Behrouz, et al.
Publicado: (2018)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening
por: Hiller, Adriana-Maria, et al.
Publicado: (2022)

Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010)

Imaging in alpha-1 antitrypsin deficiency: a window into the disease
por: Huang, Yuh-Chin Tony, et al.
Publicado: (2021)

Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative
por: Crossley, Diana, et al.
Publicado: (2020)

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years
por: Mostafavi, Behrouz, et al.
Publicado: (2019)

Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
por: Mostafavi, Behrouz, et al.
Publicado: (2017)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
por: Tanash, Hanan A, et al.
Publicado: (2016)

Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42
por: Schramm, Georg Rüdiger, et al.
Publicado: (2021)

Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 years
por: Piitulainen, Eeva, et al.
Publicado: (2017)

Acoustic radiation force impulse (ARFI) elastography in a cohort of alpha-1 antitrypsin-deficient individuals and healthy volunteers
por: Diaz, Sandra, et al.
Publicado: (2018)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population
por: Tanash, Hanan, et al.
Publicado: (2020)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
por: Greulich, Timm, et al.
Publicado: (2016)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe α1-antitrypsin deficiency
por: Hollander, Camilla, et al.
Publicado: (2007)

Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals
por: Sandström, Caroline S, et al.
Publicado: (2008)

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012)

There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements
por: Stockley, James A, et al.
Publicado: (2021)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency
por: Wood, Alice M, et al.
Publicado: (2008)

Does Augmentation with Alpha1-Antitrypsin Affect Neutrophil Extracellular Traps Formation?
por: Frenzel, Eileen, et al.
Publicado: (2012)

Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency
por: Duckers, James M, et al.
Publicado: (2010)

The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote
por: Sinden, Nicola Jane, et al.
Publicado: (2014)

Regional lung densities in alpha-1 antitrypsin deficiency compared to predicted values
por: Stoel, Berend C., et al.
Publicado: (2019)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
por: Blanco, Ignacio, et al.
Publicado: (2011)

Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential
por: Feitosa, Paulo Henrique
Publicado: (2023)

Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD
por: Hampson, Judith A., et al.
Publicado: (2016)

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank
por: Tonelli, Adriano R, et al.
Publicado: (2009)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lqe7qb9quk4sbmiqkqbs3pmrj0